Silence Therapeutics Plc American Depository Share (SLN)
Nasdaq: SLN · Pharmaceutical Preparations · London · filing with the SEC since 2010
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Report filed | Mar 5, 2026 | Feb 27, 2025 | Mar 13, 2024 | Mar 15, 2023 | Mar 17, 2022 |
| Revenue | 559 | 43,258 | 31,643 | 21,655 | · |
| Cost of revenue | 215 | 11,810 | 12,867 | 13,463 | · |
| Gross profit | 344 | 31,448 | 18,776 | 8,192 | · |
| Research and development | 67,753 | 67,883 | 56,937 | 43,550 | · |
| General and administrative | 22,344 | 26,884 | 26,222 | 25,682 | · |
| Operating income | -91,077 | -63,319 | -64,383 | -61,040 | · |
| Income before income taxes | -88,601 | -44,464 | -53,272 | -49,646 | · |
| Income tax expense | 11 | 845 | 956 | 688 | · |
| Net income including non-controlling interests | -88,612 | -45,309 | -54,228 | -50,334 | · |
| Net income | -88,612 | -45,309 | -54,228 | -50,334 | · |
| Earnings per share, basic | -0.63 | -0.33 | -0.49 | -0.52 | · |
| Earnings per share, diluted | -0.63 | -0.33 | -0.49 | -0.52 | · |
| Weighted average shares, basic | 141,694,702 | 138,752,224 | 111,277,250 | 96,584,512 | · |
| Weighted average shares, diluted | 141,694,702 | 138,752,224 | 111,277,250 | 96,584,512 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding